• Bénédicte Dumont, Dorothée Faille, and Nadine Ajzenberg.
• Département d'hématologie et d'immunologie biologiques, Hôpital Bichat, APHP, 46, rue Henri Huchard, 75877 Paris Cedex 18, France.
• Med Sci (Paris). 2011 May 1;27(5):493-500.

AbstractFor years, prevention and treatment of thromboembolic events have been restricted to the use of heparins and vitamin K antagonists. These treatments, in spite of their unquestioned efficacy, present numerous limits (hemorrhagic risk, need for regular laboratory controls). These limits call for the development of new antithrombotic drugs. This review briefly reports on three new molecules, in very advanced phases of clinical research: dabigatran (Pradaxa®), rivaroxaban (Xarelto®) and apixaban. These molecules represent new oral anticoagulants, which directly inhibit a coagulation factor (thrombin for dabigatran, factor Xa for rivaroxaban and apixaban) and do not need regular anticoagulant monitoring or dose adjustment. The approval is still restricted in France to the prophylaxis of venous thromboembolism in orthopaedics. Dabigratran will be soon available in the prevention of stroke in atrial fibrillation. With the forthcoming phase III studies to prevent and treat venous thromboembolism, anticoagulant therapy management will be most probably improved in the coming years.© 2011 médecine/sciences - Inserm / SRMS.

61 keywords...

hide…